| ||
Orexigen To Halt US Diet Drug Development Amid Dispute With FDA Wall Street Journal The setbacks have dimmed the hopes that any new prescription diet drug will hit pharmacy shelves for months and possibly years. Vivus shares dropped 7% and Arena was off 3% early Friday. Orexigen will appeal the FDA's responses and put on hold any ... See all stories on this topic » | ||
|
This as-it-happens Google Alert is brought to you by Google.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment